melisasloan2
Greenlighter
Hey Bluelighters,
I came across this update on FintechZoom.com today listing the top stock gainers, and interestingly, several of them are companies working in the psychedelic/mental health space. Here are the highlights from April 30:
It’s wild to see how much Wall Street is starting to align with topics we’ve talked about here for years. Anyone else tracking these? Think the hype is real, or are we just in another bubble?
I’m curious what the community thinks about this intersection of finance and psychonaut culture. Is mainstream attention helping or hurting?
Peace & safe journeys,
Melisa sloan
I came across this update on FintechZoom.com today listing the top stock gainers, and interestingly, several of them are companies working in the psychedelic/mental health space. Here are the highlights from April 30:
- MindMed (MNMD): +28% – Just dropped Phase II results for their LSD-based anxiety treatment.
- Compass Pathways (CMPS): +19% – Psilocybin therapy getting serious investor love.
- GH Research (GHRS): +13% – Focused on 5-MeO-DMT, which we’ve discussed a lot here.
- Axsome (AXSM) and ATAI (ATAI) also made the list.
It’s wild to see how much Wall Street is starting to align with topics we’ve talked about here for years. Anyone else tracking these? Think the hype is real, or are we just in another bubble?
I’m curious what the community thinks about this intersection of finance and psychonaut culture. Is mainstream attention helping or hurting?
Peace & safe journeys,
Melisa sloan
